Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Strategically, ARS Pharmaceuticals secured an exclusive license agreement with ALK-Abelló to commercialize neffy in Europe and other regions, which included an upfront payment of $145 million. In ...

Andrew Berens has given his Buy rating due to a combination of factors, primarily centered around Nuvalent’s promising developments in their ALK and ROS1 programs ... focusing on stocks such as Agios ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to ...

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma ...

Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...